The findings of this cohort study underscore how manufacturers have obtained and listed tertiary patents not only on top-selling drug-device combinations, like inhalers,11,12,13,14,15 glucagon-like peptide-1,16,17 and insulin,25,26 but on a wide spectrum of medications used for birth control, migraines, allergic rhinitis, chronic pain, schizophrenia, prostate cancer, psoriasis, and many other conditions. This evidence concerns the gene INS and Familial prostate cancer.